Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director

Rhea-AI Filing Summary

Maynard Ryan D reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. director Ryan D. Maynard received a grant of 90,316 deferred restricted stock units, each tied to one share of common stock. The award was made under the company’s 2018 Equity Incentive Plan.

The units vest if he continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, settlement in common stock is deferred until the earlier of three months after he leaves the board or ceases service due to death or disability, a qualifying change in control, or ten years from the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Maynard Ryan D

Role null

Type	Security	Shares	Price	Value
Grant/Award	Deferred Restricted Stock Unit	90,316	$0.00	--

Holdings After Transaction: Deferred Restricted Stock Unit — 90,316 shares (Direct, null)

Footnotes (1)

1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

Key Figures

Deferred RSU grant: 90,316 units Post-transaction DRSU holdings: 90,316 units DRSU-to-share ratio: 1 unit : 1 share +2 more

5 metrics

Deferred RSU grant 90,316 units Deferred restricted stock units granted to director on transaction date

Post-transaction DRSU holdings 90,316 units Total deferred restricted stock units held after this grant

DRSU-to-share ratio 1 unit : 1 share Each DRSU represents one share of common stock

Plan source 2018 Equity Incentive Plan Grant made under company’s 2018 Equity Incentive Plan, as amended

Maximum deferral period 10 years Settlement deferred until up to ten years from transaction date if earlier events do not occur

Key Terms

Deferred Restricted Stock Unit, 2018 Equity Incentive Plan, change in control, Board of Directors

4 terms

Deferred Restricted Stock Unit financial

"Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share"

2018 Equity Incentive Plan financial

"granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)"

change in control financial

"a change in control (as defined in the DRSU agreement)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Board of Directors financial

"after the Reporting Person's resignation or removal from the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maynard Ryan D

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Restricted Stock Unit	(1)	06/16/2026		A		90,316		(2)	(2)	Common Stock	90,316	$0	90,316	D

Explanation of Responses:

1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).

2. Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

	/s/ Ryan Maynard	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Ryan D. Maynard?

IOVANCE BIOTHERAPEUTICS reported that director Ryan D. Maynard received 90,316 deferred restricted stock units. Each unit represents a right to receive one share of common stock, granted as director compensation under the company’s 2018 Equity Incentive Plan.

How many deferred restricted stock units did IOVA grant to director Ryan D. Maynard?

Ryan D. Maynard was granted 90,316 deferred restricted stock units. These units are a form of equity compensation that, upon settlement, convert into an equal number of IOVANCE BIOTHERAPEUTICS common shares, subject to vesting and deferral conditions.

When do Ryan D. Maynard’s IOVA deferred restricted stock units vest?

The deferred restricted stock units vest if Maynard continues providing service until the earlier of the first anniversary of the grant date or the day before IOVANCE BIOTHERAPEUTICS’ next annual shareholder meeting, according to the award’s service-based vesting terms.

When will Ryan D. Maynard receive IOVA common shares from his deferred restricted stock units?

Common shares are issued only after a deferral period. Settlement occurs at the earlier of three months after Maynard leaves the board or service ends due to death or disability, a qualifying change in control, or ten years from the grant date.

What does each IOVA deferred restricted stock unit granted to Ryan D. Maynard represent?

Each deferred restricted stock unit represents a contingent right to receive one share of IOVANCE BIOTHERAPEUTICS common stock. The rights are granted under the company’s 2018 Equity Incentive Plan and are subject to specified vesting and settlement conditions.

Is Ryan D. Maynard’s IOVA Form 4 transaction a market purchase or sale?

The Form 4 shows a grant of deferred restricted stock units, not a market trade. The transaction code is an award acquisition, so no shares were bought or sold on the open market in this transaction.